Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

22.19
-1.4300-6.05%
Post-market: 22.220.0300+0.14%19:53 EDT
Volume:2.63M
Turnover:59.15M
Market Cap:2.25B
PE:-27.40
High:23.79
Open:23.46
Low:21.97
Close:23.62
52wk High:36.44
52wk Low:13.53
Shares:101.47M
Float Shares:89.94M
Volume Ratio:0.97
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8100
EPS(LYR):-0.8100
ROE:-8.11%
ROA:-18.55%
PB:1.82
PE(LYR):-27.40

Loading ...

Clear Street Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

What's Going On With Beam Therapeutics Stock?

Benzinga_recent_news
·
Feb 25

Beam Therapeutics announces $500M financing facility

TIPRANKS
·
Feb 24

Beam Therapeutics Secures $500 Million Credit Facility

TIPRANKS
·
Feb 24

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 EPS $2.33, vs. FactSet Est of $1.01 Loss

MT Newswires Live
·
Feb 24

Beam Therapeutics tops Q4 profit estimates, signs financing deal

Reuters
·
Feb 24

Beam Q4 net income attributable to common stockholders hits USD 244.3 million

Reuters
·
Feb 24

Beam Therapeutics Secures $500 Million Financing Facility With Sixth Street

Reuters
·
Feb 24

Beam Therapeutics Inc - Secures up to $500 Mln Non-Dilutive Capital From Sixth Street

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Inc - Plans Ind Filing for Beam-304 With FDA in 2026

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Q4 License and Collaboration Revenue USD 114.109 Million

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

GlobeNewswire
·
Feb 24

Beam Therapeutics Inc - Credit Facility Matures in 2033 With 10% Interest Rate

THOMSON REUTERS
·
Feb 24

Press Release: Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Dow Jones
·
Feb 24

Beam Therapeutics Inc. published an update to their financial calendar

Reuters
·
Feb 24

Beam Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Feb 21

Beam Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Feb 20

Assessing Beam Therapeutics (BEAM) Valuation After New Patent Agreement Secures Base Editing IP Access

Simply Wall St.
·
Feb 16

Wedbush Remains a Buy on Beam Therapeutics (BEAM)

TIPRANKS
·
Feb 12